Navigation Links
Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases
Date:4/29/2008

NESS ZIONA, Israel and SOPHIA-ANTIPOLIS, France, April 29 /PRNewswire/ -- Foamix Ltd, a global leader in the development of dermatological foam medications and Galderma, a worldwide specialty pharmaceutical company focused on dermatology, today announced that they have signed an agreement to develop an innovative medicated foam jointly. This new treatment contains a novel drug for the therapy of certain skin diseases.

Under this agreement, Foamix will develop the foam formulation of the product and Galderma will subsequently conduct all other activities (clinical, non-clinical, etc). Foamix will receive staged payments on successful completion of the technical milestones of the project.

About Foamix:

Headquartered in Ness Ziona, Israel, Foamix Ltd. is a leading developer of topical foams for dermatology and gynecology. Foamix's state-of-the-art foams provide controlled delivery of a variety of active ingredients. Foamix is a privately held company, whose business model is based on partnering with leading pharma companies to develop products utilizing its proprietary foam technologies. Foamix is currently collaborating with 10 pharmaceutical companies on 11 projects in the development of proprietary dermatological and gynecologic foam drugs, and has its own in-house pipeline of dermatological and gynecological drugs in foam presentation. Foamix holds 4 US patents and has 62 US patents pending, with further filings worldwide.

For additional information, please visit http://www.foamix.co.il.

About Galderma:

Galderma, created in 1981 as a joint venture between Nestle and L'Oreal, is a fully integrated specialty pharmaceutical company dedicated exclusively to the field of dermatology. The Company is present in 65 countries, with over 1,000 sales representatives and is committed to improving the health of skin with an extensive line of products to treat a range of dermatol
'/>"/>

SOURCE Foamix Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
2. ESBATechs Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
3. Breakthrough Large Scale Transfection Technology Accelerates Cell-Based Assay Development
4. Report on 750 New Medicines in Development for Cancer Released in Baton Rouge
5. Pregnant Women Need Omega-3 to Boost Infant Development
6. Aida Announces New Anti-Cancer Drug Under Development
7. ViroPharma Announces Discontinuation of HCV-796 Development
8. FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
9. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
10. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
11. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... sale to Galderma of all rights to Restylane, Perlane, ... for $1.4 billion in cash, pursuant to the previously ... acquisition of Galderma. "We are pleased ... company that is firmly committed to the aesthetic dermatology ...
(Date:7/10/2014)... BURLINGTON, Mass. , July 10, 2014 /PRNewswire/ ... three-quarters of surveyed infectious disease (ID) specialists are ... Medicines Company,s Orbactiv (oritavancin) for use as OPAT, ... to prescribe these agents to their hospital inpatients. ... percent) of OPAT patients are initiated on OPAT ...
(Date:7/10/2014)... CVS Caremark Corporation (NYSE: CVS ) ... quarterly dividend of $0.275 (27.5 cents) per share on the ... 2014, to holders of record on July 21, 2014. ... dedicated to helping people on their path to better health ... United States . Through the company,s more than 7,600 ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... AlloSource, one of the nation,s largest non-profit providers of ... procedures and the world,s largest processor of live cellular bone ... judged by the ColoradoBiz Top Company awards program. ... for the past decade, AlloSource saved and enhanced the lives ...
... Health Organization has issued a warning to medical travelers: ... heels of a growing threat of an antibiotic-resistant superbug, ... the region in India where it was discovered. "Many ... or knee replacements, ACL surgeries, root canals and spinal ...
Cached Medicine Technology:AlloSource Named Colorado's Top Healthcare Company 2New York Plastic Surgery News: Medical Tourists Beware of Drug-Resistant Superbug NDM-1 2
(Date:7/10/2014)... New York, US (PRWEB) July 10, 2014 ... . , Merrill DataSite recently streamed the live webinar ... featuring a discussion from a group of several M&A ... are seeing in the broader energy transaction marketplace. These ... hot and how the deal market in this sector ...
(Date:7/10/2014)... A Forever Recovery , an ... off to a great start and gives them a ... launched a new Eating Disorders section of its website ... , Different types of eating disorders ... Disorders (DSM-IV), including anorexia nervosa, bulimia nervosa, and EDNOS ...
(Date:7/10/2014)... July 10, 2014 (HealthDay News) -- Nature, not nurture, ... of individual chimpanzees, a new study finds. "As ... comes to cognitive [thinking] abilities in chimpanzees," William Hopkins ... said in a news release from the journal ... insight into the evolution of intelligence in humans, Hopkins, ...
(Date:7/10/2014)... 10, 2014 (HealthDay News) -- Men who have a ... cancer, a new study suggests. But the risk ... not involved with the study said more research is ... accurate. For the study, Harvard researchers analyzed data ... for 24 years, starting in 1986. During that time, ...
(Date:7/10/2014)... aggression, who research issues ranging from child abuse to ... of the International Society for Research on Aggression (ISRA) ... State University is hosting the prestigious world meeting, which ... "We are excited to be bringing together leading scholars ... produce fresh ideas about the causes, consequences and solutions ...
Breaking Medicine News(10 mins):Health News:Register to Download Merrill DataSite's Report: Capitalizing on the Shifting Sands of the Energy Market 2Health News:Latest A Forever Recovery Launches Eating Disorders Section on Website 2Health News:Like Humans, Chimps' Smarts May Rely on Genes 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3Health News:Georgia State hosts national conference on aggression 2Health News:Georgia State hosts national conference on aggression 3
... Mothers who are depressed respond differently to their crying ... according to brain scans at the University of Oregon, ... in non-depressed moms. An infant crying is normal, ... says Jennifer C. Ablow, professor of psychology. For years, ...
... This release is available in Spanish . ... and cooperators have confirmed what many pollen-sensitive people already suspected: ... longer and ends later. Ragweed pollen in some ... almost a month longer than it did in 1995, and ...
... , TUESDAY, Feb. 22 (HealthDay News) -- Despite suggestions ... skin condition known as atopic eczema, a new British ... to relieve sufferers. "Although the outcome is disappointing ... eczema, the outcome of the trial is very clear," ...
... HealthDay Reporter , TUESDAY, Feb. 22 (HealthDay News) -- ... increased risk of ischemic stroke, which typically occurs when blood ... fatty deposits within blood vessels, a new Danish study contends. ... pronounced for triglyceride fats than it is for cholesterol, even ...
... researcher believes there could be a new drug compound ... also help with controlling cholesterol. Salman Hyder, the ... biomedical sciences in the College of Veterinary Medicine and ... discovered that a small molecule, Ro 48-8071, initially developed ...
... leap forward in understanding Huntington,s disease may give patients ... cells and post-mortem brain tissue of Huntington,s disease patients ... that causes brain nerve cells to die. Toning down ... the chain reaction and kept those cells alive, according ...
Cached Medicine News:Health News:Crying baby draws blunted response in depressed mom's brain 2Health News:Crying baby draws blunted response in depressed mom's brain 3Health News:USDA study confirms links between longer ragweed season and climate change 2Health News:Softening Water Does Not Seem to Ease Eczema 2Health News:High Triglyceride Levels Linked to Increased Stroke Risk: Study 2Health News:High Triglyceride Levels Linked to Increased Stroke Risk: Study 3Health News:Compound used to block cholesterol could also kill breast cancer, MU researcher finds 2Health News:Huntington's disease breakthrough equals hope for patients 2
... interoperative placement to stent the ... and continent urinary diversions. Supplied ... for one-time use. CAUTION: Periodic ... not remain indwelling more than ...
... a device that provides effective cutting and simultaneous ... to provide the urologist with the same touch ... the approximate speed and the same ease of ... but with a 45% greater zone of ...
Used for stone manipulation and removal in the renal pelvis under direct vision. Supplied sterile in peel-open packages. Intended for one-time use....
Used for stone manipulation and removal in the renal pelvis under direct vision. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: